Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study-Reference-Cited by-同舟云学术

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study

Published:2018-04 Issue: Volume:Volume 13 Page:1229-1237
ISSN:1178-2005
Container-title:International Journal of Chronic Obstructive Pulmonary Disease
language:en
Short-container-title:COPD

Author:

Greulich Timm^ORCID,Kostikas Konstantinos,Gaga Mina,Aalamian-Mattheis Maryam,Lossi Nadine S,Patalano Francesco^ORCID,Nunez Xavier,Pagano Veronica A.,Fogel Robert^ORCID,Vogelmeier Claus,Clemens Andreas

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pulmonary and Respiratory Medicine,General Medicine

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease;Cochrane Database of Systematic Reviews;2023-06-05

2. Clinically important deterioration: a composite tool for managing patients with COPD;Respiratory Medicine;2022-12

3. Effectiveness of COPD treatment with the combination of tiotropium/olodaterol in Polish standard clinical practice as measured by the improvement of CCQ: an observational study;Polish Archives of Internal Medicine;2022-05-27

4. Efficacy of ICS versus Non-ICS Combination Therapy in COPD: A Meta-Analysis of Randomised Controlled Trials;International Journal of Chronic Obstructive Pulmonary Disease;2022-05

5. Indacaterol/glycopyrronium affects lung function and cardiovascular events in patients with chronic obstructive pulmonary diseases: A meta-analysis;Heart & Lung;2021-07